doi:10.3969/j.issn.1004-583X.2025.08.011

Abstract

CLC Number:

R725.7

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.08.011

https://www.lchc.cn/EN/Y2025/V40/I8/731

References 42

[1]	Frontera WR, Ochala J. Skeletal muscle: A brief review of structure and function[J]. Calcif Tissue Int, 2015, 96(3):183-195.
[2]	Fu Y, Zhao S, Zhang C, et al. The impact of sarcopenia on postoperative complications and survival outcomes after robotic colorectal cancer surgery: A study based on single-center propensity score matching[J]. J Robot Surg, 2024, 19(1):13. doi: 10.1007/s11701-024-02133-z pmid: 39615012
[3]	Sugimura K, Miyata H, Kanemura T, et al. Impact of preoperative skeletal muscle mass and physical performance on short-term and long-term postoperative outcomes in patients with esophageal cancer after esophagectomy[J]. Ann Gastroenterol Surg, 2022, 6(5):623-632. doi: 10.1002/ags3.12560 pmid: 36091312
[4]	Liu C, Li Y, Xu Y, et al. The impact of preoperative skeletal muscle mass index-defined sarcopenia on postoperative complications and survival in gastric cancer: An updated meta-analysis[J]. Eur J Surg Oncol, 2025, 51(3):109569.
[5]	Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care[J]. Appl Physiol Nutr Metab, 2008, 33(5):997-1006.
[6]	Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in pants with solid tumours of the respiratory and gastrointestinal tracts: A population-based study[J]. Lancet Oncol, 2008, 9(7):629-635.
[7]	Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: Revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(1):16-31. doi: 10.1093/ageing/afy169 pmid: 30312372
[8]	Iritani S, Imai K, Takai K, et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma[J]. J Gastroenterol, 2014, 50 (3): 323-332.
[9]	Cho K, Oh D, Kim T, et al. Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy[J]. J Clin Oncol, 2017, 35 (4_suppl): 460-460.
[10]	Carey EJ, Lai JC, Wang CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease[J]. Liver Transpl, 2017, 23(5):625-633.
[11]	Zeng X, Shi ZW, Yu JJ, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: A multicentre study in China[J]. J Cachexia Sarcopenia Muscle, 2021, 12(6):1948-1958. doi: 10.1002/jcsm.12797 pmid: 34520115
[12]	Chinese Society of Gastroenterology,Chinese Medical Association. Chinese consensus on the management of liver cirrhosis[J]. J Dig Dis, 2024, 25(6):332-352.
[13]	Chen H, Yang C, Yan S, et al. Sarcopenia in cirrhosis: From pathophysiology to interventional therapy[J]. Exp Gerontol, 2024,196:112571.
[14]	Zhang Q, Lei S, Zhang Q, et al. Establishment of a prognostic model for hospitalized cirrhotic patients with infection based on lumbar muscle mass[J]. Heliyon, 2024, 10(4):e25739.
[15]	Yao J, Zhou X, Yuan L, et al. Prognostic value of the third lumbar skeletal muscle mass index in patients with liver cirrhosis and ascites[J]. Clin Nutr, 2020, 39(6):1908-1913. doi: S0261-5614(19)33018-3 pmid: 31472986
[16]	Zhang S, Zhou T, Wu M, et al. Sarcopenia is associated with new-onset acute biliary infection within 1 year in patients with hepatitis B virus-related decompensated cirrhosis[J]. Eur J Gastroenterol Hepatol, 2025, 37(1):100-105.
[17]	Br VK, Sarin SK. Acute-on-chronic liver failure: Terminology,mechanisms and management[J]. Clin Mol Hepatol, 2023, 29 (3): 670-689.
[18]	Wang J, Bai J, Wang H, et al. Relationship between skeletal muscle index at the third lumbar vertebra with infection risk and long-term prognosis in patients with acute-on-chronic liver failure[J]. Front Nutr, 2024,10 1327832.
[19]	Geng N, Kong M, Zhang J, et al. Dynamic skeletal muscle loss and its predictive role on 90-day mortality in patients with acute-on-chronic liver failure[J]. Front Nutr, 2025,12: 1446265.
[20]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(5):418-434.
[21]	Teng ML, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2023, 29(Suppl):S32-S42.
[22]	Roh E, Hwang SY, Yoo HJ, et al. Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: A nationwide multicenter prospective study[J]. Hepatol Int, 2022, 16(3):545-554.
[23]	Feng Z, Zhao F, Wang Z, et al. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations[J]. BMC Gastroenterol, 2024, 24(1):111. doi: 10.1186/s12876-024-03192-0 pmid: 38491346
[24]	Harring M, Golabi P, Paik JM, et al. Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis[J]. Clin Gastroenterol Hepatol, 2023, 21(11):2876-2888.e5.
[25]	Zhao Q, Yin Y, Deng Y. Metabolic associated fatty liver disease and sarcopenia additively increase mortality: A real-world study[J]. Nutr Diabetes, 2023, 13(1):21. doi: 10.1038/s41387-023-00250-6 pmid: 37968264
[26]	Hsieh YC, Joo SK, Koo BK, et al. Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease[J]. Liver Int, 2021, 41(3):494-504.
[27]	Lee YK, Koo BK, Joo SK, et al. Low-quality muscle mass rather than normal-quality muscle mass determines fibrosis progression in biopsy-proven NAFLD[J]. Aliment Pharmacol Ther, 2023, 58(3):322-333.
[28]	原发性肝癌诊疗指南(2024年版)[J]. 肿瘤综合治疗电子杂志, 2024, 10(3):17-68.
[29]	Yang S, Zhang Z, Su T, et al. CT-based skeletal muscle loss for predicting poor survival in patients with hepatocellular carcinoma experiencing curative hepatectomy plus adjuvant transarterial chemoembolization: A preliminary retrospective study[J]. Eur J Med Res, 2022, 27(1):131. doi: 10.1186/s40001-022-00760-6 pmid: 35879734
[30]	Wang X, Wang J, Li J, et al. Effect of skeletal muscle index on post-embolization syndrome of hepatocellular carcinoma after transarterial chemoembolization[J]. BMC Gastroenterol, 2024, 24(1):333. doi: 10.1186/s12876-024-03427-0 pmid: 39350028
[31]	Polvieng T, Hongjinda S, Thienhiran A, et al. Effect of sarcopenia on the prognosis of clinical outcomes in patients with hepatocellular carcinoma after hepatic resection[J]. Am Surg, 2024, 90(6):1447-1455. doi: 10.1177/00031348241241713 pmid: 38516765
[32]	Akaoka M, Haruki K, Taniai T, et al. Clinical significance of cachexia index in patients with hepatocellular carcinoma after hepatic resection[J]. Surg Oncol, 2022,45:101881.
[33]	Matsunaga T, Satio H, Sakano YU, et al. Skeletal muscle mass before second-line chemotherapy correlates with subsequent prognosis and rate of late-line chemotherapy in patients with unresectable gastric cancer[J]. Anticancer Res, 2023, 43(11):5051-5059. doi: 10.21873/anticanres.16704 pmid: 37909949
[34]	Alnimri F, Sivakumar J, Sutherland T, et al. Pre-operative low muscle mass is associated with major complications and lower recurrence-free survival after gastric cancer surgery[J]. ANZ J Surg, 2021, 91(3):316-322.
[35]	Juez LD, Priego P, Bajawi M, et al. Impact of sarcopenic obesity on long-term cancer outcomes and postoperative complications after gastrectomy for gastric cancer[J]. J Gastrointest Surg, 2023, 27(1):35-46.
[36]	Ma Z, Liu R, Liu H, et al. New scoring system combining computed tomography body composition analysis and inflammatory-nutritional indicators to predict postoperative complications in stage II-III colon cancer[J]. J Gastroenterol Hepatol, 2023, 38(9):1520-1529.
[37]	Raoul P, Cintoni M, Coppola A, et al. Preoperative low skeletal muscle mass index assessed using L3-CT as a prognostic marker of clinical outcomes in pancreatic cancer patients undergoing surgery: A systematic review and meta-analysis[J]. Int J Surg, 2024, 110(10):6126-6134.
[38]	Grillot J, D'Engremont C, Parmentier AL, et al. Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn's disease[J]. Clin Nutr, 2020, 39(10):3024-3030. doi: 10.1016/j.clnu.2020.01.001 pmid: 31980183
[39]	Wang R, Ding X, Tian Z, et al. Body composition changes and related factors in patients with ulcerative colitis: A retrospective single-center study in China[J]. Med Sci Monit, 2022,28:e933942.
[40]	中华医学会外科学分会胰腺外科学组. 中国急性胰腺炎诊治指南(2021)[J]. 浙江实用医学, 2021, 26(6):511-519,535.
[41]	Lin C, Zhang J, Wang C, et al. The impact of skeletal muscle index at the third lumbar spine on nosocomial deterioration and short-term prognosis in acute pancreatitis:Aretrospective observational study[J]. PeerJ, 2024,12:e17283.
[42]	Xu L, Yu H, Chen L, et al. The modified computed tomography severity index combined with low skeletal muscle mass can better predict the severity of hypertriglyceridemia-induced pancreatitis[J]. J Hepatobiliary Pancreat Sci, 2022, 29(12):1336-1345.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 42

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. CLINICAL FOCUS, 2014, 29(4): 441-442.
[2]	. [J]. Clinical Focus, 2013, 28(1): 87-0.
[3]	. [J]. Clinical Focus, 2012, 27(2): 159-160.
[4]	. [J]. CLINICAL FOCUS, 2011, 26(11): 986-988.
[5]	LUO Yan-jun;HU Chi-jun;LU Ming. Barrier function of esophagogastric junction and acid reflux in children with wheezing [J]. CLINICAL FOCUS, 2011, 26(9): 769-771.
[6]	. [J]. CLINICAL FOCUS, 2010, 25(14): 1238-1239.
[7]	. [J]. CLINICAL FOCUS, 2009, 24(22): 1988-1988.
[8]	. [J]. CLINICAL FOCUS, 2009, 24(3): 235-237.
[9]	. [J]. CLINICAL FOCUS, 2008, 23(20): 1472-1473.
[10]	. [J]. CLINICAL FOCUS, 2006, 21(14): 1054-1055.
[11]	. [J]. CLINICAL FOCUS, 2006, 21(12): 874-874.
[12]	. [J]. CLINICAL FOCUS, 2005, 20(16): 927-928.
[13]	. [J]. CLINICAL FOCUS, 2004, 19(10): 572-573.
[14]	. [J]. CLINICAL FOCUS, 2002, 17(9): 519-520.
[15]	. [J]. CLINICAL FOCUS, 2002, 17(5): 268-268.